Gumokimab, also called AK111, is an anti-IL-17A monoclonal antibody that Akeso has already tested out in a separate phase 3 ...

After raising more than $142 million in venture capital earlier this year to support its liver transplant technology, OrganOx is adding a zero to the total with a new acquisition offer fr | The deal ...

Amid a frozen over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its ...

With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

At AbbVie, bretisilocin will slot into a well-established neuroscience unit. AbbVie has deals with Gedeon Richter, the source ...

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

The Supreme Court is allowing the Trump administration to axe $783 million in federal research funding, reversing a lower ...

Thermo Fisher Scientific cut the ribbon to open a highly automated manufacturing plant in North Carolina—featuring a ...

Arena BioWorks has laid off 30% of its workers 19 months after launching with $500 million and visions of bringing the Bell ...

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...